Interpace Biosciences IncOTCQX US:IDXG
- LAST PRICE2.6800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.2000/ 1
- Ask / Lots2.8400/ 1
- Open / Previous Close2.6800 / 2.6800
- Day Range
- 52 Week Range
- Volume3,150
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IDXG |
|---|---|---|
| 09:39 ET | 250 | 2.68 |
| 10:24 ET | 500 | 2.63 |
| 10:26 ET | 1200 | 2.59 |
| 12:50 ET | 700 | 2.59 |
| 03:14 ET | 500 | 2.68 |
Nov 4, 2024
Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results, from 4:30PM ET on Monday Nov 04, 2024 by Dow Jones
4:30PM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Interpace Biosciences Inc | 11.8M | 2.4x | --- |
Streamline Health Solutions Inc | 12.3M | -9.2x | --- |
Prophase Labs Inc | 18.3M | -0.5x | --- |
Selectis Health Inc | 4.2M | -0.7x | --- |
Psychemedics Corp | 13.8M | -4.6x | --- |
Avem Health Partners Inc | 10.1M | 3.6x | --- |
Company Information
Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer by leveraging the technology in personalized medicine for improved patient diagnosis and management. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, RespriDX, and BarreGEN. PancraGEN is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts. PanDNA is a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors. ThyGeNEXT is for the diagnosis of thyroid cancer from thyroid nodules. RespriDX differentiates lung cancer of primary versus metastatic origin.
Contact Information
- Headquarters
- Waterview Plaza Suite 310, 2001 Route 46PARSIPPANY, NJ, United States 07054
- Phone
- 412-224-6100
- Fax
- 302-636-5454
Executives
- President, Chief Executive Officer, Director
- Thomas Burnell
- Chief Financial Officer
- Christopher Mccarthy
- Independent Director
- Vijay Aggarwal
- Independent Director
- Joseph Keegan
- Independent Director
- Fortunato Rocca
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $11.8M |
|---|---|
Revenue (TTM) | $44.9M |
Shares Outstanding | 4.4M |
Interpace Biosciences Inc does not pay a dividend. | |
Beta | 0.69 |
EPS | $1.10 |
Book Value | $-3.48 |
P/E Ratio | 2.4x |
Price/Sales (TTM) | 0.3 |
Price/Cash Flow (TTM) | 2.3x |
Operating Margin | 14.14% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
